Showing 5461-5470 of 8207 results for "".
- Provectus: PV-10 Clinical Data On The Treatment Of Melanoma To Be Presented At ESMO 2014https://practicaldermatology.com/news/20140915-provectus_pv-10_clinical_data_on_the_treatment_of_melanoma_to_be_presented_at_esmo_2014/2459120/Provectus Biopharmaceuticals, Inc. will present clinical data on PV-10 at the European Society for Medical Oncology's 2014 Congress (ESMO) in Madrid, Spain. The presentation, titled "Subgroup efficacy in patients receiving intralesional rose bengal t
- FDA Accepts Investigational New Drug Application for Alphaeon's Neurotoxin Evosyalhttps://practicaldermatology.com/news/20140909-fda_accepts_investigational_new_drug_application_for_alphaeons_neurotoxin_evosyal/2459123/The FDA accepted the Investigational New Drug (IND) Application to conduct clinical studies for EVOSYAL, an botulinum toxin Type A neurotoxin that was acquired by Alphaeon last year as part of the acquisition of Evolus Inc. “The product development team
- Novan's Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model: Presentationhttps://practicaldermatology.com/news/20140909-novans_nitric_oxide_drug_candidate_inhibits_growth_of_papillomavirus_in_translational_animal_model_presentation/2459124/Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced that Novan's nitric oxide drug candidate SB206 was shown to inhibit papilloma growth in a preclinical animal study. About two-thirds of healthy American adults are infected with human papillom
- Pacific Edge Granted US Patent for Melanoma Detectionhttps://practicaldermatology.com/news/20140905-pacific_edge_granted_us_patent_for_melanoma_detection/2459127/The United States Patent and Trademark Office granted Pacific Edge Limited, a cancer diagnostics company, US Patent Number 8,822,149 covering "Prognosis Prediction for Melanoma Cancer." The patent covers the technology being used to develop a melanoma prognostic test that will e
- Novan to Present Antiviral Preclinical Results of Nitric Oxide-Releasing Drug Candidates for the Treatment of Papillomavirushttps://practicaldermatology.com/news/20140903-novan_to_present_antiviral_preclinical_results_of_nitric_oxide-releasing_drug_candidates_for_the_treatment_of_papillomavirus/2459131/Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, will present antiviral data from a preclinical animal study at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), ta
- Advanced Dermatology and Cosmetic Surgery (ADCS Clinics) Announces the Acquisition of Fort Collins Skin Clinichttps://practicaldermatology.com/news/20140903-advanced_dermatology_and_cosmetic_surgery_adcs_clinics_announces_the_acquisition_of_fort_collins_skin_clinic/2459132/ADCS Clinics (“ADCS”) announced it has completed the acquisition of Fort Collins Skin Clinic in Fort Collins, Colorado; a dermatology practice owned by Dr. Brad Baack and Dr. Andy Kalajian (both Board Certified Dermatologist and fellowship trained Mohs Micrographic Surgeons). Baack and Kalajian, wit
- Solace International Issues Recall of Dermatend Original and Dermatend Ultrahttps://practicaldermatology.com/news/20140902-solace_international_issues_recall_of_dermatend_original_and_dermatend_ultra/2459134/Solace International, Inc. is voluntarily recalling all lots of Dermatend Original and Dermatend Ultra in all sizes and dosage form to the distributor/wholesaler level. A mole should be removed under the supervision of a dermatologist. Dermatend is not FDA approved, thus has not
- Dermira Completes $51 Million Financing and Expands Management Team and Board of Directorshttps://practicaldermatology.com/news/20140821-dermira_completes_51_million_financing_and_expands_management_team_and_board_of_directors/2459139/Dermira, a specialty biopharmaceutical focused on dermatology, completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock S
- Justin Chickles Joins myoscience as Vice President of Commercial Development & Johanna Beckmen Becomes General Manager of Aestheticshttps://practicaldermatology.com/news/20140812-justin_chickles_joins_myoscience_as_vice_president_of_commercial_development__johanna_beckmen_becomes_general_manager_of_aesthetics/2459148/Justin Chickles is now Vice President of Commercial Development and Johanna Beckmen is now promoted to General Manager of Aesthetics of Myoscience, Inc. Chickles Said, "Myoscience's ioveradegrees treatment is poised to become a transformative therapy for patients living with pain.The pas
- FDA Warns of Adverse Events Associated with Unapproved Use of Expression Injectable as a Dermal Fillerhttps://practicaldermatology.com/news/20140806-fda_warns_of_adverse_events_associated_with_unapproved_use_of_expression_injectable_as_a_dermal_filler/2459150/The FDA reported that it has become aware of adverse events associated with the unapproved use of the Expression product, hyaluronic acid that is packaged in a syringe, as a dermal filler. Events have included swelling, tenderness, firmness, lumps, bu